Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) have been given an average recommendation of “Moderate Buy” by the six brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $8.30.

Several brokerages have recently issued reports on CGTX. HC Wainwright upped their target price on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a report on Thursday, December 19th. B. Riley upgraded shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $1.00 to $1.50 in a research note on Thursday, December 19th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $11.00 price objective on shares of Cognition Therapeutics in a report on Thursday, December 19th.

Institutional Trading of Cognition Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in Cognition Therapeutics during the 4th quarter worth $26,000. Virtu Financial LLC purchased a new stake in shares of Cognition Therapeutics in the third quarter valued at about $27,000. Mercer Global Advisors Inc. ADV boosted its stake in shares of Cognition Therapeutics by 33.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after buying an additional 24,050 shares during the period. Finally, Sigma Planning Corp boosted its stake in shares of Cognition Therapeutics by 14.6% during the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after buying an additional 25,050 shares during the period. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Stock Down 1.8 %

Shares of Cognition Therapeutics stock opened at $0.68 on Friday. Cognition Therapeutics has a 52 week low of $0.34 and a 52 week high of $2.95. The firm’s 50 day moving average is $0.57 and its two-hundred day moving average is $0.77. The firm has a market capitalization of $28.33 million, a P/E ratio of -0.70 and a beta of 0.95.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.